TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
RCUS

Arcus Biosciences Inc

Healthcare · Biotechnology

25.20$ -1.2% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

Arcus Biosciences Inc (RCUS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 41 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement RCUS
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
32 31 145 39 48 26 28 160 26 33 17 41 117
3.0 5.0 3.0 2.0 3.0 2.0 2.0 3.0 2.0
32 31 145 39 48 26 28 160 24 30 15 41 110
82 93 109 115 123 101 122 139 141 121 122 113 497
30 29 32 30 30 28 28 29 27 26 29 24 106
112 122 161 145 153 129 150 168 166 144 149 137 596
-80 -91 -16 -106 -105 -103 -122 -8.0 -142 -114 -134 -96 -486
1.0 2.0 1.0 0.0 1.0 2.0 1.0 2.0 3.0 14 3.0 3.0 23
-69 -80 -4.0 -93 -92 -94 -112 -8.0 -135 -98 -128 -91 -452
2.0 1.0 1.0 1.0
-71 -81 -4.0 -93 -92 -94 -112 -8.0 -135 -98 -128 -91 -452
-67 -77 7.0 -91 -89 -89 -108 4.0 -130 -81 -123 -85 -419

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?